Pharmaceuticals

Clinical research leader Novotech offers a strategic roadmap for biotech and pharma, aiming to de-risk and accelerate the complex world of autoimmune drug development.

As rising temperatures amplify India's public health risks, a new campaign tackles a persistent 'know-do gap' in dehydration treatment. But is consumer education enough?

Regeneron's Q2 results reveal soaring sales from Dupixent and EYLEA HD, a pivotal pipeline, and a major financial reset with Sanofi. What's next?

Knight Therapeutics set a high bar in Q1. As it preps its Q2 results, we look at the strategy and market forces that will define its next chapter.

AB2 Bio's partnership with Nippon Shinyaku for Tadekinig alfa signals a new era for ultra-rare pediatric care and highlights a savvy biotech financing strategy.

Lōkahi Therapeutics aims to turn 15 injections into one for its pain drug LT-100, a move that could transform patient care and unlock major commercial value.

Latigo Biotherapeutics' new drug LTG-001 shows superior, faster pain relief than Vicodin in a major trial, offering a potent new tool against the opioid crisis.

Skincare brand Valitic hit 2M customers, but the real story is how its e-commerce success provides the cash flow for parent Innocan Pharma's biotech ambitions.

While big chains falter, Good Neighbor Pharmacy, backed by a $300B giant, just won #1 in customer trust. Here’s the investment case for their model.

Octapharma's $1.5 billion Rock Hill facility promises 1,500 high-paying jobs. But beyond the local boom, it signals a critical shift in securing America's medical supply chain.

A small logistics firm with big ambitions breaks ground in rural Alabama, promising a $500M biomanufacturing hub to help secure America's drug supply.

Clene Inc. heads to the Canaccord Growth Conference with promising ALS data and a clear regulatory path, but faces a critical test of investor confidence.

As Akebia Therapeutics preps its Q2 report, all eyes are on Vafseo's uptake, a declining Auryxia, and a costly R&D push into rare kidney diseases.

With a novel drug targeting an unaddressed cause of glaucoma, Qlaris Bio adds a seasoned expert to its board, signaling a pivotal push toward market entry.

Processa Pharmaceuticals acquires Vidya Therapeutics and its key asset, VT-7208, backed by a $200M financing that radically overhauls the company's strategy.

Qnovia secures a license for a novel peptide, D8, that kills superbugs differently. Can this university-born innovation turn the tide on antibiotic resistance?

Par Health's new ready-to-use Sugammadex syringe tackles medication errors and workflow delays, signaling a major shift in how essential medicines are delivered.

An FDA panel's nod to controversial peptides seems to validate Hydreight's long-term strategy. But a closer look reveals a long road and a deep data gap.

Shionogi launches XOCOVA, the first oral pill to prevent COVID after exposure. With a 67% efficacy rate and a $1,400 price tag, who will it protect?